– ISRAEL – Atox Bio, developer of therapeutics for severe infections, today announced that it appointed biotech veteran Daniel D. Burgess as its Chairman of the Board of Directors.
Mr. Burgess was founder, President and CEO of Rempex Pharmaceuticals Inc., an antibiotic company that was sold to the Medicines Company in a transaction valued at up to $475 million. Previously, Mr. Burgess was President and CEO of Mpex Pharmaceuticals Inc., a company that advanced an inhaled antibiotic for cystic fibrosis into Phase 3 before it was acquired by Aptalis Inc. in 2011. Mr. Burgess has also held senior executive positions at a number of other biotechnology companies and served as a Director and Chairman of the Audit Committee of Santarus Inc. until its acquisition by Salix Inc. in 2014 for $2.7 billion.
Dan Burgess stated, “I am excited to work with the management team and investors at Atox Bio to help bring this potentially important new therapy through development. AB103 has the opportunity to benefit patients in several critical care markets with significant medical need and the clinical data to date is encouraging.”
Dan Teleman, CEO of Atox Bio, stated, “The board and I welcome Dan Burgess as our new chairman. Dan’s experience in successfully building and leading anti-infective companies will greatly benefit Atox Bio as we prepare for our pivotal study with AB103 in NSTI and expand into other severe infections.”
About Atox Bio
Established in 2003 by Prof. Raymond Kaempfer and Dr. Gila Arad from the Hebrew University of Jerusalem and Yissum, Atox Bio is a clinical stage biotechnology company that develops novel immunemodulators for critically ill patients with severe infections.
AB103, Atox Bio’s lead product, is being developed for Necrotizing Soft Tissue Infections (NSTI) and other severe infections. AB103 is the first product specifically developed for NSTI and has received Orphan Drug status and Fast Track designation from the FDA as well as a positive opinion from the EMA’s Committee for Orphan Medicinal Products.
Atox Bio completed an investment of up to $23M from a syndicate consisting of SR One, OrbiMed and Lundbeckfond Ventures and signed a contract with BARDA worth up to $24M.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.